AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 FEB 11 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corp. (GNBT) announced the recent presentation of a poster at the Keystone Symposium, "Rational Design of Vaccines and Immunotherapies," on a novel cancer vaccination method developed by scientists and collaborators at its Antigen Express subsidiary.
The poster was presented by Dr. Gary Ostroff, a consultant.
"There was considerable interest in the novel Antigen Express DNA transfection method to convert tumor cells in situ into effective immunotherapeutic agents," said Ostroff. "A big problem today is promoting helper T lymphocytes to build an effective immune response against cancer and virally infected cells. Antigen Express scientists have identified a mechanism boosting immunoregulatory T-cell responses to combat cancer and infectious diseases."
Dr. Eric von Hofe, vice president, technology development at Antigen Express, explained why this method of immunostimulation is so potent. "The biological mechanism of this type of stimulation is well understood and we have a commanding patent position on the necessary agents and their methods of use. The immune system has basically two types of lymphocytes. Killer T lymphocytes eliminate tumors or ...
Source: HighBeam Research, Company reports on mechanism for immunotherapy cure of prostate...